Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695501 delivery device pharmacokinetic comparison study
NL-OMON42895Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adalimumab-adbm in rheumatoid arthritis (RA), Crohn's disease, autoimmune colitis and 3 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: AUC0-1368, Cmax and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
adalimumab-adbm
03
Conditions
rheumatoid arthritis (RA)Crohn's diseaseautoimmune colitispsoriasishidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON42895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42895.